摘要Objective:To evaluate the role of class Ⅲ β-tubulin (TUBB3),thymidylate synthase (TS),thymidine phosphorylase (TP),and excision repair cross-complementing group 1 (ERCC1) in clinical outcome of advanced gastric cancer patients receiving capecitabine plus paclitaxel or cisplatin.Methods:The clinical data and tumor specimens from 57 advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel (cohort 1,n=36) and capecitabine plus cisplatin (cohort 2,n=21) were retrospectively collected,and TUBB3,TS,TP,and ERCC1 expressions were detected by real-time quantitative PCR.The associations between expressions of biomarkers and response or survival were analyzed statistically.Results:The median age of 57 patients was 57 years (range:27-75 years) with 38 males and 19 females.Of all patients,the response rates of patients with high TP,low TP and high TS,low TS expressions were 57.1％,27.6％ (P=0.024),and 55.2％,28.6％ (P=0.042),respectively.Among cohort 1,the response rates and median overall survivals of patients with low and high TUBB3 expressions were 61.1％ vs.33.3％ (P=0.095) and 13.8 months vs.6.6 months (P=0.019),respectively; the response rate (87.5％) of patients with low TUBB3 and high TP expressions was higher than that (14.3％) of patients with high TUBB3 and low TP expressions (P=0.01).Among cohort 2,the response rates of patients with low ERCC1 and high ERCC1 expressions were 45.5％ and 20.0％ respectively (P=0.361).Conclusion:TUBB3,TS and TP expressions could predict the response of advanced gastric cancer patients receiving capecitabine-based and paclitaxel-based chemotherapy.These results will be further confirmed in future large samples.